Characteristic | Patients n = 47, mean ± SD, (%) |
---|---|
Duration of SLE, yrs | 8.9 ± 7.3 (range 1–31) |
Age at diagnosis of SLE, yrs | 29.5 ± 12.6 (range 10–56) |
Smoking (≥ 10 pk/yrs), % | 30 |
Hypertension (SBP ≥ 140 and DBP = 90 mm Hg, % | 16 |
Diabetes mellitus (fasting glucose > 130 mg/dl or on therapy), % | 4 |
Hyperlipidemia (cholesterol ≥ 240 or triglycerides > 150 mg/dl), % | 45 |
Any atherosclerotic risk factor, % | 70 |
Postmenopausal status, % | 9 |
Total SLEDAI | 12 ± 10.4 (range, 1–47) |
Total SLICC | 3.3 ± 2.4 |
Prednisone therapy, % | 87 |
Prednisone average dose, mg/day | 7.5 ± 7.3 (range, 0–40) |
Prednisone, yrs | 7.2 ± 6.7 (range, 0–30) |
Cyclophosphamide therapy, % | 30 |
Years of cyclophosphamide therapy | 0.64 ± 0.90 (range 0–3) |
Mycophenalate or methotrexate therapy, % | 17 |
Hydroxychloroquine or chloroquine therapy, % | 47 |
Aspirin, warfarin, or clopidogrel, % | 21 |
DNA titer (dilutions) | 31.6 ± 50 |
ANA titer (dilutions) | 353 ± 447 |
Antiphospholipid antibody-positive, % | 57 |
IgM anticardiolipin antibody, IU | 9.3 ± 15 |
IgG anticardiolipin antibody, IU | 12.6 ± 19 |
IgA anticardiolipin antibody, IU | 5.9 ± 11.7 |
Smith antibody-positive, % | 30 |
SSA antibody-positive, % | 40 |
C3, mg/dl | 99.4 ± 3.6 |
C4, mg/dl | 20.8 ± 25.3 |
CH50, mg/dl | 84.4 ± 36.4 |
C-reactive protein, mg/dl | 1.13 ± 1.5 |
Erythrocyte sedimentation rate, mm/h | 24.6 ± 25.7 |
Data presented as mean ± SD. SLEDAI: SLE disease activity index; SLICC: SLE International Collaborating Clinics Damage Index; ANA: antinuclear antibody.